6:29 PM
 | 
Nov 05, 2012
 |  BC Extra  |  Top Story

BioMarin jumps on GALNS data

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) jumped $11.66 (31%) to $49.07 on Monday after reporting that once-weekly 2 mg/kg IV GALNS met the primary endpoint in the Phase III MOR-004 trial to...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >